030 Efficacy and safety of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis: Single-blind, randomized trial

Patients with systemic scleroderma (SSc) typically develop Raynaud’s phenomenon (RP) and persistent digital ischemia and often develop digital ulcers (DUs). Currently, there is no satisfactory treatment for RP and DUs in SSc. We recently demonstrated that botulinum toxin A (BTX-A) injection was effective for the treatment of RP and DUs in SSc patients. However, the efficacy of BTX-B injection has never been examined. The objective was to assess...